



United Food and Commercial Workers Unions and
Participating Employers Health and Welfare Fund

Managed Pharmacy Report

September 2024

Nancy J. Eid, Vice President, Sr. Pharmacy Consultant

| Agenda

January – June 2024 Key Performance Indicators
2025 OptumRx Biosimilar Strategy

| January-June 2024

Key Performance Indicators


Key Performance Indicators

- Total Plan Paid increased 19% per member per month (PMPM)
- Trend drivers: specialty and non-specialty drug mix
- The number of specialty drug utilizers decreased from 18 to 14 (-22%)
- Rebates lowered PMPM costs by 29%
- Diabetes remains the number one driver of trend

Key Performance Indicators			
Description	Jan-June 2024	Jan-June 2023	Change
Members	1,254	1,329	-6%
Number of Utilizers	611	655	-7%
Total Rxs	3,302	3,576	-8%
Total Plan Paid	\$87,3011	\$77,8318	12%
Plan Paid PMPM	\$232	\$195	19%
Specialty PMPM	\$110	\$80	38%
Non-Specialty PMPM	\$122	\$115	6%
Generic Dispensing Rate	85%	87%	-3%
Member Paid Share	5.5%	5.8%	-7%
Specialty Percent of Plan Cost	47%	41%	16%

Top Indications by Plan Cost

The top five disease states accounted for 72% of total Plan Paid PMPM



Top 20 Drugs by Plan Cost

Current Rank	Prev Rank	Drug Name	Therapy Class	Utilizers	Total Plan Paid	Current Plan Paid PMPM	Prev Plan Paid PMPM
1	2	SOMAVERT*	Growth Hormones	1	\$75,065	\$19.95	\$17.89
2	3	BIKTARVY	HIV-Multiclass Combo	5	\$55,344	\$14.71	\$10.55
3	15	SIGNIFOR LAR*	Endocrine Disorders	1	\$54,539	\$14.49	\$3.88
4	1	HUMIRA PEN*	Chronic Inflammatory Disease	3	\$52,584	\$13.97	\$19.60
5	4	OZEMPIC	GLP-1 Receptor Agonists	3.0	\$50,058	\$13.30	\$9.82
6	-	REVLIMID	Oncology	1	\$48,434	\$12.87	\$0.00
7	6	JARDIANCE	SGL T-2 Inhibitors and Combos	29	\$41,194	\$10.95	\$7.00
8	-	SPRYCEL*	Oncology	1	\$35,810	\$9.52	\$0.00
9	8	LENALIDOMIDE*	Oncology	1	\$34,760	\$9.24	\$5.96
10	5	MAYZENT*	Multiple Sclerosis	1	\$30,250	\$8.04	\$7.21
11	9	OXBRYTA*	Sickle Cell Anemia	1	\$25,004	\$6.64	\$5.68
12	10	COSENTYX PEN*	Chronic Inflammatory Disease	1	\$22,538	\$5.99	\$5.43
13	62	MOUNJARO	GLP-1 Receptor Agonists	11	\$22,212	\$5.91	\$0.45
14	-	SKYRIZI PEN*	Chronic Inflammatory Disease	1	\$20,933	\$5.56	\$0.00
15	17	ELIQUIS	Oral Anticoagulants	14	\$17,682	\$4.70	\$3.12
16	11	DUPIXENT*	Chronic Inflammatory Disease	1	\$14,114	\$3.75	\$4.56
17	12	SYM TUZA	HIV-Multiclass Combo	1	\$13,674	\$3.63	\$4.47
18	14	FARXIGA	SGL T-2 Inhibitors and Combos	11	\$12,609	\$3.35	\$4.19
19	24	WEGOVY	GLP-1 Antiobesity Agents	3	\$10,211	\$2.71	\$1.56
20	28	XARELTO	Oral Anticoagulants	10	\$9,249	\$2.46	\$1.27

*Specialty Drugs

| 2025 OptumRx Biosimilar Strategy

2025 OptumRx Biosimilar Strategy

- Effective January 1, 2025, OptumRx will prefer FDA-approved Humira and Stelara biosimilars on its commercial formularies for members new to therapy.
- Participants already prescribed Humira will be able to continue Humira, if they chose, until preferred biosimilars are interchangeable and do not require a new prescription.
 - Currently, there are eight unique participants using Humira, compared to four in 2023.
- Formulary selections should be appropriate for more than 95% of plan participants.

Select Formulary Changes –Biosimilars			
Current		2025	
Tier 2 with PA • Humira • Amjevita HW & LW • Cyclezo & Adalimumbab-adbm • Hyrimoz & Adalimumbab-adaz	Tier 3 with PA All other branded and unbranded biosimilars	Tier 2 with PA • Amjevita for Nuvaila (LW) • Amjevita for Amgen (HW)	Tier 3 with PA • Requires 6-month trial of preferred biosimilars • Humira for new patients; all other branded and unbranded biosimilars
Tier 2 with PA • Stelara		Tier 2 with PA • Stelara • Wezlana for Nuvaila (LW & HW) – interchangeable	

- Standard formularies will include high wholesale acquisition cost (WAC) and low WAC biosimilars options, as they become available.
- Cost differences between high and low WAC biosimilars are included on the following page.

2025 OptumRx Biosimilar Strategy

Net cost comparison between the reference drug and the biosimilar, based on a 30 days' supply.

Drug Name	Ingredient Cost	2024 Net Ingredient Cost	2025 Net Ingredient Cost	Net Cost Savings
Humira	\$6,600	\$2,000	\$1,600	20%
Amjevita for Amgen (HW)	\$6,300	\$2,400	\$1,400	30%
Amjevita for Nuvaila (LW)	\$1,200	NOT AVAILABLE	\$1,200	40%

Drug Name	Ingredient Cost	2024 Net Ingredient Cost (30 days' supply)	2025 Net Ingredient Cost	Net Cost Savings
Stelara	\$27,000	\$8,200	\$7,600	10%
Wezlana (HW)	\$26,500	NOT AVAILABLE	\$6,600	20%
Wezlana (LW)	\$13,800	NOT AVAILABLE	\$6,600	20%

Source: 2025 Biosimilar Strategy, OptumRx August 2024.

2025 OptumRx Biosimilar Strategy

The Member Experience

- Prescribers will be notified via secure direct messaging ~60 days prior to the effective date.
- Notifications will be patient-specific and include guidance of how to support members through this transition.
- Network pharmacies will receive the 1/1 formulary changes following the OptumRx standard process.
- Patients taking an interchangeable biosimilar will not require a new prescription.
- Optum is adding the preferred biosimilars to their manufacturer-funded coupon programs (Variable Copay Solution and Copay Card Accumulator Adjustment).

Rebate Guarantees

- Humira and Stelara are currently eligible for rebates.
- Rebates will apply to Humira claims until there is a decision to terminate the allowance for continuation of therapy (COT).
- Preferred biosimilars will be eligible for rebates where available from manufacturers.
- The Fund's current contract includes provisions for the 'rebate credit' process used by PBMs to reconcile then-current annual rebate guarantees with material changes in the rebates available in the marketplace that that may occur mid-contract.

Next Steps

- Confirm elections regarding the **low-WAC** only or **the high-WAC** only biosimilar option.
- A hybrid of the two can also be accommodated if supply chain issues with the biosimilars.
- Segal recommends adoption of the low-WAC only option, which will result in lower-upfront costs for both the Fund and the members, without compromising access to quality healthcare.

